Related Experiment Video
Updated: Jan 2, 2026
Measurement of γHV68 Infection in Mice
Published on: November 22, 2011
Recombinant luciferase-expressing murine gammaherpesvirus 68 as a tool for rapid antiviral screening
Abstract:
Murine gammaherpesvirus 68 (MHV-68) provides a valuable tool to screen novel therapeutic strategies against oncogenic gammaherpesviruses. The development and characterization of antiviral agents usually depend on appropriate screening assays. The aim of this study was to develop rapid and sensitive method for testing antiviral compounds against gammaherpesviruses. For this purpose, a recombinant MHV-68 expressing firefly luciferase (MHV-68/LUC) was constructed. The conditions for MHV-68/LUC infection in Vero cells suitable for novel antiviral screening assay in 96-well plate format were then optimized. The sensitivity of MHV-68/LUC to acyclovir (ACV) and ganciclovir (GCV) was measured by the optimized luciferase activity reduction assay. The 50% inhibition concentration (IC50) values for ACV and GCV were comparable to those determined by conventional plaque reduction assay. Therefore, the luciferase activity reduction assay can efficiently replace the plaque reduction assay. The great advantages of novel assay are represented by the significant reduction in assay time and rapid and objective measurement of the assay. In order to evaluate whether the luciferase activity reduction assay could be used as a screening system for novel antivirals, newly synthesized quinolone/quinoline derivatives were tested for their effects on the replication of MHV-68/LUC in vitro. The compound 2-(1-(b-D-Xylopyranosyl)-1,2,3-triazol-4-yl)-3,4-dibenzyloxy-quinoline showed significant antiviral activity and its IC50 against MHV-68/LUC was estimated to be 1,76 µg/ml. However, this compound was not suitable for in vivo testing due to its narrow selectivity index (SI = 11). Keywords: MHV-68; antiviral screening; luciferase; quinolone/quinoline derivatives.
Insights
This study developed a rapid luciferase assay for screening antiviral compounds against murine gammaherpesvirus 68 (MHV-68). The new assay is faster and more objective than traditional methods, enabling efficient testing of novel antiviral agents.
Area of Science:
- Virology
- Drug Discovery
- Biotechnology
Background:
- Murine gammaherpesvirus 68 (MHV-68) is a model for studying oncogenic gammaherpesviruses.
- Developing effective antiviral agents requires robust screening assays.
- Current methods for antiviral screening can be time-consuming and subjective.
Purpose of the Study:
- To develop a rapid and sensitive method for screening antiviral compounds against gammaherpesviruses.
- To establish a luciferase-based assay for MHV-68 using a recombinant virus.
- To optimize conditions for high-throughput screening in a 96-well plate format.
Main Methods:
- Construction of a recombinant MHV-68 expressing firefly luciferase (MHV-68/LUC).
- Optimization of MHV-68/LUC infection in Vero cells for 96-well plate assays.
- Measurement of antiviral activity using a luciferase activity reduction assay.
- Comparison of results with conventional plaque reduction assays.
- Testing of novel quinolone/quinoline derivatives for antiviral activity.
Main Results:
- The optimized luciferase activity reduction assay demonstrated sensitivity comparable to plaque reduction assays.
- The assay significantly reduces assay time and allows for rapid, objective measurements.
- A novel quinolone/quinoline derivative showed significant in vitro antiviral activity against MHV-68/LUC.
- The most active compound had an IC50 of 1.76 µg/ml but a narrow selectivity index (SI=11), limiting in vivo application.
Conclusions:
- The luciferase activity reduction assay is an efficient and effective replacement for plaque reduction assays in antiviral screening.
- This rapid assay facilitates the discovery and development of novel antiviral therapies against gammaherpesviruses.
- Further optimization of lead compounds is necessary to improve selectivity for in vivo applications.
